Pressure Ulcers Stage III Clinical Trial
Official title:
The Use of an Oral Mixture of Arginine, Glutamine and Beta-hydroxy-beta-methylbutyrate for the Treatment of Pressure Ulcers
To investigate whether an oral nutritional supplement of a mixture of arginine, glutamine and HMB for a maximum period of four weeks is more beneficial than the standard dietary approach to the healing of pressure ulcers, and to examine whether the use of it can reduce admissions and length of hospitalizations for these patients.
All patients would be assessed by a dietitian to ensure them receiving nutritional support
of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding
method. During the study period, vitamin C and zinc supplement would not be given.
Nutritional supplement other than that provided by the dietitian to meet the energy and
protein requirement would not be given. The pressure ulcers would be cared according to the
"Basic nursing standards for patient care: Wound dressing - Version 5" published by the
Hospital Authority Head Office.
The treatment group would also be given 2 Sackets of a mixture of arginine, glutamine and
HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral
feeding.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04311229 -
Effectiveness of Negative-Pressure Wound Therapy
|
N/A | |
Recruiting |
NCT05894291 -
Comparaison of Two Prone Position Techniques on Occurence of Pressure Sores in ICU
|
N/A | |
Completed |
NCT02222454 -
Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers
|
N/A | |
Not yet recruiting |
NCT05649332 -
Study to Evaluate the Performance and Safety of the Medical Device Argogen
|
N/A | |
Completed |
NCT05130814 -
EmoLED Medical Device Treatment of Second and Third Stage Pressure Ulcers
|
N/A | |
Recruiting |
NCT05496296 -
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
|
N/A | |
Completed |
NCT03283787 -
Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytalâ„¢ to Standard of Care in Stage 3 or 4 Pressure Injuries
|
N/A |